Creative Medical Technology Holdings CELZ Institutional Ownership

Updated Oct 11, 2026

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) appeared in the 13F filings of 15 institutional investors for the quarter ended June 30, 2026.

• Their combined stake equaled 5.74% of outstanding shares in Q2 2026, up from 2.62% in Q1 2026.
• Total shares held in Creative Medical Technology Holdings rose 285.38% from Q1 2026, while the number of holders rose 50.00% from Q2 2025.
• Looking at the 15 holders of CELZ individually, 11 added to their positions, 2 reduced their stakes and 2 left their positions unchanged.
• The aggregate institutional position in Creative Medical Technology Holdings was 372.91K shares at the end of Q2 2026, up 276.15K from the prior quarter and up 314.13K from a year earlier.
• Hudson Bay Capital Management LP led 13F holders of CELZ with 135.17K shares as of June 30, 2026, or 2.08% of shares outstanding.
• Among holders that already owned Creative Medical Technology Holdings, the biggest buyers in Q2 2026 were XTX Topco Ltd (+12.3K shares), Tower Research Capital LLC (+2.76K shares), UBS Group AG (+2.06K shares) and SBI Securities Co., Ltd. (+42 shares).
• On the other side, among holders that kept a position in Creative Medical Technology Holdings, the largest reductions in Q2 2026 came from Geode Capital Management, LLC (-12.49K shares) and Morgan Stanley (-20 shares).
• According to Business Quant data, the leading holders of CELZ for Q2 2026 were Hudson Bay Capital Management LP (135.17K shares), Anson Funds Management LP (105.55K shares), Armistice Capital, LLC (42K shares), XTX Topco Ltd (26.56K shares), Geode Capital Management, LLC (25.8K shares), Vanguard Capital Management LLC (20.35K shares), Vanguard Fiduciary Trust Co (5.52K shares), Tower Research Capital LLC (4.85K shares), Global Retirement Partners, LLC (4.12K shares) and UBS Group AG (2.06K shares).